Payment overview · 2025
General Payments
$2,539.14
92 reported records · 13 companies
Healthcare provider profile · identity verified
Anwer Jaffri, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TERRE HAUTE, IN · NPI 1508974189
Verified facts
What the public records show
CMS Open Payments records show Anwer Jaffri, M.D. received $2,539.14 in general payments during 2025 across 92 reported records.
Gilead Sciences, Inc. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Dovato, Epclusa, Pifeltro, Rukobia.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Descovy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Epclusa as an associated drug or biological on 4711 records involving 2021 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Epclusa by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arikayce by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Pifeltro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $765.83 | 30.2% | 10 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $750.72 | 29.6% | 34 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $298.75 | 11.8% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $152.94 | 6.0% | 6 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.04 | 5.4% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $115.09 | 4.5% | 6 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $88.84 | 3.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.15 | 2.3% | 3 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.32 | 2.1% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $33.53 | 1.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.31 | 1.3% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $31.91 | 1.3% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $20.71 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,939.14 | 91 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $600.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $600.00 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $521.88 | 23 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $174.01 | 9 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $160.91 | 8 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $137.04 | 11 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $101.43 | 5 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $88.84 | 4 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $58.15 | 3 | 2025 |
Source payment records
|
|||||
| VIBATIV Normalized: vibativ |
Drug | Cumberland Pharmaceuticals, Inc. | $52.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 110 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Epclusa epclusa |
2025 | Epclusa | 2024 | 24 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Epclusa open payments reported associated product |
CMS Open Payments — General Payments 4711 supporting records · 2021 recipient NPIs · example record 1234350832 |
Epclusa · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
166 | 163 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 13 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
110 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Hyclate | Doxycycline Hyclate | 595 | 266 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 16 |
| Furosemide | Furosemide | 225 | 22 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 213 | 142 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 199 | 151 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 166 | 163 |
| Daptomycin | Daptomycin | 164 | 23 |
| Eliquis | Apixaban | 151 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 148 | 24 |
| Jardiance | Empagliflozin | 138 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 115 | 21 |
| Dovato | Dolutegravir Sodium/Lamivudine | 110 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 100 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 15 |
| Potassium Chloride | Potassium Chloride | 90 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 87 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 61 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 84 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 11 |
| Levetiracetam | Levetiracetam | 82 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | suppressed |
| Metformin Hcl | Metformin Hcl | 69 | suppressed |
| Metronidazole | Metronidazole | 67 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 64 |
| Meropenem | Meropenem | 65 | 14 |
| Gabapentin | Gabapentin | 63 | 12 |
| Famotidine | Famotidine | 60 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 19 |
| Ertapenem | Ertapenem Sodium | 58 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Carvedilol | Carvedilol | 55 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | suppressed |
| Lisinopril | Lisinopril | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Losartan Potassium | Losartan Potassium | 42 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 41 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Tivicay | Dolutegravir Sodium | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 19 |
| Nystatin | Nystatin | 33 | 19 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 29 | 20 |
| Amoxicillin | Amoxicillin | 28 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Klayesta | Nystatin | 27 | 12 |
| Descovy | Emtricitabine/Tenofov Alafenam | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Entecavir | Entecavir | 24 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 24 | 11 |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 14 |
| Cefazolin Sodium | Cefazolin Sodium | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Cefdinir | Cefdinir | 18 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Linezolid | Linezolid | 16 | 15 |
| Rukobia | Fostemsavir Tromethamine | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 15 |
| Azithromycin | Azithromycin | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Rifampin | Rifampin | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Pifeltro | Doravirine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,539.14 · 92 records | Gilead Sciences, Inc. | APRETUDE, AVYCAZ, Arikayce, CABENUVA, CAPVAXIVE, DALVANCE, DOVATO, Epclusa, Hizentra, MAVYRET, Miro3D, NUZYRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PIFELTRO, RUKOBIA, TEFLARO, VIBATIV, VOWST, ZENPEP, ZERBAXA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error